In vitro development of resistance to DX-619 and other quinolones in enterococci

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 6, 2006, Pages 1268-1273

  Wickman, Paul A ^a   Black, Jennifer A ^a   Smith Moland, Ellen ^a   Thomson, Kenneth S ^a   Hanson, Nancy D ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ciprofloxacin; Gatifloxacin; Levofloxacin; Moxifloxacin; Mutational frequency

Indexed keywords

BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DX 619; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE AMPLIFICATION; GENE FREQUENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; POLYMERASE CHAIN REACTION; PYRROLIDINES; QUINOLINES; QUINOLONES; SEQUENCE ANALYSIS, DNA;

EID: 33845352174     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl421     Document Type: Article

References (9)

1. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-44.
2. Moellering RC,Jr. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992; 14: 1173-6.
3. Fujikawa K, Chiba M, Tanaka M et al. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrob Agents Chemother 2005; 49: 3040-5.
4. el Amin N, Jalal S, Wretlind B. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 947-9.
5. Grohs P, Houssaye S, Aubert A et al. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother 2003; 47: 3542-7.
6. Kanematsu E, Deguchi T, Yasuda M et al. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1998; 42: 433-5.
7. Onodera Y, Okuda J, Tanaka M et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46: 1800-4.
8. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
9. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.